4-(4-Methylpiperazino)aniline
CAS: 16153-81-4
Ref. 3D-FM35780
2g | Discontinued | ||
5g | Discontinued | ||
10g | Discontinued | ||
25g | Discontinued | ||
2kg | Discontinued |
Product Information
- Otava-Bb Bb7110920492
- Akos Bb-8657
- Akos B021941
- 4-(4-Methylpiperazine)Aniline
- 4-(4-Methylpiperazin-1-Yl)Phenylamine
- 4-(4-Methylpiperazin-1-Yl)Aniline
- 1-(4-Aminophenyl)-4-Methylpiperazine
- 4-(4-Aminophenyl)-1-Methylpiperazin-1-Ium
- 4-Methyl-1-(4-aminophenyl)piperazine
- 4-(4-Methyl-piperazino)aniline
- See more synonyms
- 4-(4-Methylpiperazin-1-yl)benzenamine
4-(4-Methylpiperazino)aniline is a molecule that has been shown to be orally bioavailable and has a tyrosine kinase inhibitory profile. The kinetic, amide, and safety profiles of this compound have been studied in vitro and in vivo. 4-(4-Methylpiperazino)aniline was found to be safe for use in humans at doses up to 100 mg/kg. The pharmacokinetic profile of this compound suggests that it could be administered as a once-daily oral dose. 4-(4-Methylpiperazino)aniline is being developed as a cancer therapy for the treatment of cancers with epidermal growth factor receptor (EGFR), such as lung cancer, breast cancer, and colorectal cancer.